JP2017500362A - ピラゾロ［１，５−ａ］ピリジン誘導体およびその使用方法 - Google Patents
ピラゾロ［１，５−ａ］ピリジン誘導体およびその使用方法 Download PDFInfo
- Publication number
- JP2017500362A JP2017500362A JP2016542956A JP2016542956A JP2017500362A JP 2017500362 A JP2017500362 A JP 2017500362A JP 2016542956 A JP2016542956 A JP 2016542956A JP 2016542956 A JP2016542956 A JP 2016542956A JP 2017500362 A JP2017500362 A JP 2017500362A
- Authority
- JP
- Japan
- Prior art keywords
- fluoro
- alkyl
- compound according
- pyrazolo
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(C(C(N1c2ccccc2)=O)=*(*)N(*)C1=O)=O Chemical compound CC(C(C(N1c2ccccc2)=O)=*(*)N(*)C1=O)=O 0.000 description 12
- AAMHEFOXVHMCGB-UHFFFAOYSA-N CC(C1(CC1)C(Nc1ccccc1)=O)=O Chemical compound CC(C1(CC1)C(Nc1ccccc1)=O)=O AAMHEFOXVHMCGB-UHFFFAOYSA-N 0.000 description 1
- JEAHUZOVGCOTHE-UHFFFAOYSA-N CC(C=C1)=CCC1F Chemical compound CC(C=C1)=CCC1F JEAHUZOVGCOTHE-UHFFFAOYSA-N 0.000 description 1
- PEXOFQJGAALAQD-NCAUGAEKSA-N CC(N1c(cc2)ccc2F)=CC=C(C(Nc(cc2)cc(F)c2OC2=CC(C3CCSCC3)=CN/C2=C\C=[N-])=O)C1=O Chemical compound CC(N1c(cc2)ccc2F)=CC=C(C(Nc(cc2)cc(F)c2OC2=CC(C3CCSCC3)=CN/C2=C\C=[N-])=O)C1=O PEXOFQJGAALAQD-NCAUGAEKSA-N 0.000 description 1
- YFJYMIAPUGRUQQ-KMWWMJHUSA-N CC(N1c(cc2)ccc2F)=CC=C(C(Nc(cc2)cc(F)c2OC2=CC(N3CCOCC3)=CN/C2=C\C=N)=O)C1=O Chemical compound CC(N1c(cc2)ccc2F)=CC=C(C(Nc(cc2)cc(F)c2OC2=CC(N3CCOCC3)=CN/C2=C\C=N)=O)C1=O YFJYMIAPUGRUQQ-KMWWMJHUSA-N 0.000 description 1
- QGFXQROZPVUHDZ-NBIWDDIVSA-N CC/C=C(/[C@@H](C)/C=C(\c1ccn[nH]1)/Oc(ccc(NC(C1=CC=CN(c(cc2)ccc2F)C1=O)=O)c1)c1F)\C=N Chemical compound CC/C=C(/[C@@H](C)/C=C(\c1ccn[nH]1)/Oc(ccc(NC(C1=CC=CN(c(cc2)ccc2F)C1=O)=O)c1)c1F)\C=N QGFXQROZPVUHDZ-NBIWDDIVSA-N 0.000 description 1
- WBSABPMHMHDOBW-FFVZZNFRSA-N CC1=CCCN/C1=C\CC=N Chemical compound CC1=CCCN/C1=C\CC=N WBSABPMHMHDOBW-FFVZZNFRSA-N 0.000 description 1
- LCBCRARUNGLQPS-UHFFFAOYSA-N CCN(C(C(C(O)=O)=CN1c(cc2)ccc2F)=O)C1=O Chemical compound CCN(C(C(C(O)=O)=CN1c(cc2)ccc2F)=O)C1=O LCBCRARUNGLQPS-UHFFFAOYSA-N 0.000 description 1
- PLJDQXBSGWEWIU-UHFFFAOYSA-N CCN(C(C(C(OCC)=O)=CN1c(cc2)ccc2F)=O)C1=O Chemical compound CCN(C(C(C(OCC)=O)=CN1c(cc2)ccc2F)=O)C1=O PLJDQXBSGWEWIU-UHFFFAOYSA-N 0.000 description 1
- ZPVWEJKBIMNEHT-HDNUPPOLSA-N CCN(C=C(C(N/C(/C=C(\C(O/C=C/[C@@H](CNCC(C=N)=C)C(N(C)C)=O)=C)/F)=C/C)=O)C(N1/C(/C=C\C(F)=C)=C/C)=O)C1=O Chemical compound CCN(C=C(C(N/C(/C=C(\C(O/C=C/[C@@H](CNCC(C=N)=C)C(N(C)C)=O)=C)/F)=C/C)=O)C(N1/C(/C=C\C(F)=C)=C/C)=O)C1=O ZPVWEJKBIMNEHT-HDNUPPOLSA-N 0.000 description 1
- LBSOPNVTFIKMKA-XOPBRNACSA-N CCN(C=C(C(Nc(cc1)cc(F)c1OC1=CC(Nc2ccccn2)=CN/C1=C\C=N)=O)C(N1c(cc2)ccc2F)=O)C1=O Chemical compound CCN(C=C(C(Nc(cc1)cc(F)c1OC1=CC(Nc2ccccn2)=CN/C1=C\C=N)=O)C(N1c(cc2)ccc2F)=O)C1=O LBSOPNVTFIKMKA-XOPBRNACSA-N 0.000 description 1
- CQORYPWKMDLUOV-SNAWJCMRSA-N CN(/C=C(\C=C)/N)N Chemical compound CN(/C=C(\C=C)/N)N CQORYPWKMDLUOV-SNAWJCMRSA-N 0.000 description 1
- RCIQYZZCWDQVEA-ASZGPRNHSA-N CN(CC1)CCN1c(nc1)ccc1C(C=C1Oc(c(F)c2)ccc2NC(C2=CC=CN(c(cc3)ccc3F)C2=O)=O)=CN/C1=C\C=N Chemical compound CN(CC1)CCN1c(nc1)ccc1C(C=C1Oc(c(F)c2)ccc2NC(C2=CC=CN(c(cc3)ccc3F)C2=O)=O)=CN/C1=C\C=N RCIQYZZCWDQVEA-ASZGPRNHSA-N 0.000 description 1
- DBSOWXCVHMTIBB-UHFFFAOYSA-N C[n]1ncc(Nc2c[n]3nccc3c(Oc(c(F)c3)ccc3[N+]([O-])=O)c2)c1 Chemical compound C[n]1ncc(Nc2c[n]3nccc3c(Oc(c(F)c3)ccc3[N+]([O-])=O)c2)c1 DBSOWXCVHMTIBB-UHFFFAOYSA-N 0.000 description 1
- FODNRELKGUNDIC-UHFFFAOYSA-N C[n]1ncc(Nc2c[n]3nccc3c(Oc(ccc(N)c3)c3F)c2)c1 Chemical compound C[n]1ncc(Nc2c[n]3nccc3c(Oc(ccc(N)c3)c3F)c2)c1 FODNRELKGUNDIC-UHFFFAOYSA-N 0.000 description 1
- LNJMHEJAYSYZKK-UHFFFAOYSA-N Cc1ncccn1 Chemical compound Cc1ncccn1 LNJMHEJAYSYZKK-UHFFFAOYSA-N 0.000 description 1
- KRZCOLNOCZKSDF-UHFFFAOYSA-N Nc(cc1)ccc1F Chemical compound Nc(cc1)ccc1F KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 1
- WPJGHIVGAOVUAT-UHFFFAOYSA-N OC(C1=CC=CN(c(cc2)ccc2F)C1=O)=O Chemical compound OC(C1=CC=CN(c(cc2)ccc2F)C1=O)=O WPJGHIVGAOVUAT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361920819P | 2013-12-26 | 2013-12-26 | |
| US61/920,819 | 2013-12-26 | ||
| PCT/US2014/071040 WO2015100117A1 (en) | 2013-12-26 | 2014-12-18 | Pyrazolo[1,5-a]pyridine derivatives and methods of their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017500362A true JP2017500362A (ja) | 2017-01-05 |
| JP2017500362A5 JP2017500362A5 (enExample) | 2018-02-01 |
Family
ID=52293273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016542956A Pending JP2017500362A (ja) | 2013-12-26 | 2014-12-18 | ピラゾロ［１，５−ａ］ピリジン誘導体およびその使用方法 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US9914731B2 (enExample) |
| EP (2) | EP3087070B1 (enExample) |
| JP (1) | JP2017500362A (enExample) |
| KR (1) | KR20160110390A (enExample) |
| CN (1) | CN106029661B (enExample) |
| AU (1) | AU2014370186A1 (enExample) |
| BR (1) | BR112016015057A2 (enExample) |
| CA (1) | CA2934667A1 (enExample) |
| CL (1) | CL2016001604A1 (enExample) |
| DK (1) | DK3087070T3 (enExample) |
| EA (2) | EA029757B1 (enExample) |
| ES (1) | ES2654931T3 (enExample) |
| HU (1) | HUE037579T2 (enExample) |
| IL (1) | IL246311A0 (enExample) |
| MX (1) | MX2016008445A (enExample) |
| NO (1) | NO3014707T3 (enExample) |
| PH (1) | PH12016501232A1 (enExample) |
| PL (1) | PL3087070T3 (enExample) |
| PT (1) | PT3087070T (enExample) |
| SG (1) | SG11201605207PA (enExample) |
| SI (1) | SI3087070T1 (enExample) |
| WO (1) | WO2015100117A1 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021504367A (ja) * | 2017-11-24 | 2021-02-15 | 南京明徳新薬研発有限公司Ｍｅｄｓｈｉｎｅ Ｄｉｓｃｏｖｅｒｙ Ｉｎｃ． | ｃ−ＭＥＴ／ＡＸＬ阻害剤としてのウラシル系化合物 |
| JP2021536436A (ja) * | 2018-08-24 | 2021-12-27 | 南京薬捷安康生物科技有限公司Nanjing Transthera Biosciences Co., Ltd. | キノリン誘導体から調製される新規な阻害剤 |
| WO2023286719A1 (ja) * | 2021-07-13 | 2023-01-19 | 日本曹達株式会社 | ウラシル化合物の製造方法 |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3322706T3 (da) * | 2015-07-16 | 2021-02-01 | Array Biopharma Inc | Substituerede pyrazolo[1,5-a]pyridin-forbindelser som ret-kinaseinhibitorer |
| CN106467541B (zh) * | 2015-08-18 | 2019-04-05 | 暨南大学 | 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用 |
| CN106543145B (zh) * | 2016-10-28 | 2019-07-19 | 山西医科大学 | c-Met激酶抑剂3-(4-氟苯基)嘧啶酮-5-甲酸酰胺衍生物、制备方法与应用 |
| CA3047580A1 (en) * | 2016-12-23 | 2018-07-26 | Plexxikon Inc. | Compounds and methods for cdk8 modulation and indications therefor |
| CA3049136C (en) | 2017-01-18 | 2022-06-14 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors |
| CA3087578C (en) | 2018-01-18 | 2023-08-08 | Array Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors |
| WO2019143994A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
| CA3087354C (en) | 2018-01-18 | 2023-01-03 | Array Biopharma Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| UY38349A (es) | 2018-08-30 | 2020-03-31 | Array Biopharma Inc | Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met |
| CN112996794A (zh) | 2018-09-10 | 2021-06-18 | 阿雷生物药品公司 | 作为ret激酶抑制剂的稠合杂环化合物 |
| AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| CN110467616B (zh) * | 2019-07-01 | 2021-12-21 | 江西科技师范大学 | 含杂芳基取代哒嗪酮结构的三唑并吡嗪类化合物的制备及应用 |
| CN110330479A (zh) * | 2019-07-19 | 2019-10-15 | 南京华威医药科技集团有限公司 | 一种用作axl抑制剂的抗肿瘤化合物及其用途 |
| KR102826937B1 (ko) | 2019-09-06 | 2025-07-01 | 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 | Axl 및 c-Met 키나아제 억제 활성을 갖는 화합물 및 이의 제조와 응용 |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CA3178450A1 (en) | 2020-03-30 | 2021-10-07 | Hutchison Medipharma Limited | Amide compounds and uses thereof |
| IT202100022682A1 (it) * | 2021-09-01 | 2023-03-01 | Luigi Frati | Derivati pirimidinici e loro uso nel trattamento di tumori |
| CN116655626B (zh) * | 2023-05-24 | 2025-03-11 | 遵义医科大学 | 一种含咪唑并[l，2-a]吡啶骨架的环丙二酰胺化合物及其制备方法和用途 |
| WO2025034912A2 (en) * | 2023-08-07 | 2025-02-13 | Cogent Biosciences, Inc. | Compounds for fgfr inhibition |
| WO2025111224A1 (en) * | 2023-11-21 | 2025-05-30 | Fmc Corporation | Linked bicyclic compounds for controlling and combating invertebrate pests |
Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004506736A (ja) * | 2000-08-22 | 2004-03-04 | グラクソ グループ リミテッド | タンパク質キナーゼ阻害剤としての縮合ピラゾール誘導体 |
| JP2008504366A (ja) * | 2004-06-28 | 2008-02-14 | ブリストル−マイヤーズ スクイブ カンパニー | 縮合ヘテロ環キナーゼ阻害剤 |
| WO2008072634A1 (ja) * | 2006-12-12 | 2008-06-19 | Takeda Pharmaceutical Company Limited | 縮合複素環化合物 |
| JP2009510113A (ja) * | 2005-09-30 | 2009-03-12 | ブリストル−マイヤーズ スクイブ カンパニー | Ｍｅｔキナーゼインヒビター |
| JP2009529047A (ja) * | 2006-03-07 | 2009-08-13 | アレイ バイオファーマ、インコーポレイテッド | ヘテロ二環系ピラゾール化合物およびその使用 |
| WO2012116217A1 (en) * | 2011-02-25 | 2012-08-30 | Irm Llc | Compounds and compositions as trk inhibitors |
| CN102827186A (zh) * | 2011-06-16 | 2012-12-19 | 中国科学院上海药物研究所 | 一类吡啶并五元杂环衍生物及其制备方法和用途 |
| WO2013022519A1 (en) * | 2011-08-10 | 2013-02-14 | Merck Patent Gmbh | Pyrido-pyrimidine derivatives |
| WO2013043715A1 (en) * | 2011-09-19 | 2013-03-28 | Genentech, Inc. | Combination treatments comprising c-met antagonists and b-raf antagonists |
| JP2013516393A (ja) * | 2009-12-31 | 2013-05-13 | ハッチソン・メディファーマ・リミテッド | 特定のトリアゾロピリジンおよびトリアゾロピラジン、それらの組成物並びにそれらの使用方法 |
| WO2013074633A1 (en) * | 2011-11-14 | 2013-05-23 | Cephalon, Inc. | Uracil derivatives as axl and c-met kinase inhibitors |
| WO2013180949A1 (en) * | 2012-05-27 | 2013-12-05 | Ning Xi | Substituted quinoline compounds and methods of use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1972628A1 (en) | 2007-03-21 | 2008-09-24 | Schwarz Pharma Ag | Indolizines and aza-analog derivatives thereof as CNS active compounds |
| JP2011530511A (ja) | 2008-08-05 | 2011-12-22 | メルク・シャープ・エンド・ドーム・コーポレイション | 治療用化合物 |
-
2014
- 2014-12-18 EP EP14824711.7A patent/EP3087070B1/en not_active Not-in-force
- 2014-12-18 PT PT148247117T patent/PT3087070T/pt unknown
- 2014-12-18 DK DK14824711.7T patent/DK3087070T3/en active
- 2014-12-18 CN CN201480075903.4A patent/CN106029661B/zh not_active Expired - Fee Related
- 2014-12-18 CA CA2934667A patent/CA2934667A1/en not_active Abandoned
- 2014-12-18 EP EP17196014.9A patent/EP3309160A1/en not_active Withdrawn
- 2014-12-18 JP JP2016542956A patent/JP2017500362A/ja active Pending
- 2014-12-18 ES ES14824711.7T patent/ES2654931T3/es active Active
- 2014-12-18 EA EA201691164A patent/EA029757B1/ru not_active IP Right Cessation
- 2014-12-18 SI SI201430533T patent/SI3087070T1/en unknown
- 2014-12-18 EA EA201890061A patent/EA201890061A3/ru unknown
- 2014-12-18 AU AU2014370186A patent/AU2014370186A1/en not_active Abandoned
- 2014-12-18 BR BR112016015057A patent/BR112016015057A2/pt not_active IP Right Cessation
- 2014-12-18 MX MX2016008445A patent/MX2016008445A/es unknown
- 2014-12-18 HU HUE14824711A patent/HUE037579T2/hu unknown
- 2014-12-18 PL PL14824711T patent/PL3087070T3/pl unknown
- 2014-12-18 SG SG11201605207PA patent/SG11201605207PA/en unknown
- 2014-12-18 US US15/108,400 patent/US9914731B2/en not_active Expired - Fee Related
- 2014-12-18 WO PCT/US2014/071040 patent/WO2015100117A1/en not_active Ceased
- 2014-12-18 KR KR1020167019605A patent/KR20160110390A/ko not_active Withdrawn
-
2015
- 2015-06-23 NO NO15745380A patent/NO3014707T3/no unknown
-
2016
- 2016-06-19 IL IL246311A patent/IL246311A0/en unknown
- 2016-06-21 CL CL2016001604A patent/CL2016001604A1/es unknown
- 2016-06-22 PH PH12016501232A patent/PH12016501232A1/en unknown
-
2018
- 2018-01-24 US US15/879,175 patent/US20180148447A1/en not_active Abandoned
Patent Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004506736A (ja) * | 2000-08-22 | 2004-03-04 | グラクソ グループ リミテッド | タンパク質キナーゼ阻害剤としての縮合ピラゾール誘導体 |
| JP2008504366A (ja) * | 2004-06-28 | 2008-02-14 | ブリストル−マイヤーズ スクイブ カンパニー | 縮合ヘテロ環キナーゼ阻害剤 |
| JP2009510113A (ja) * | 2005-09-30 | 2009-03-12 | ブリストル−マイヤーズ スクイブ カンパニー | Ｍｅｔキナーゼインヒビター |
| JP2009529047A (ja) * | 2006-03-07 | 2009-08-13 | アレイ バイオファーマ、インコーポレイテッド | ヘテロ二環系ピラゾール化合物およびその使用 |
| WO2008072634A1 (ja) * | 2006-12-12 | 2008-06-19 | Takeda Pharmaceutical Company Limited | 縮合複素環化合物 |
| JP2013516393A (ja) * | 2009-12-31 | 2013-05-13 | ハッチソン・メディファーマ・リミテッド | 特定のトリアゾロピリジンおよびトリアゾロピラジン、それらの組成物並びにそれらの使用方法 |
| WO2012116217A1 (en) * | 2011-02-25 | 2012-08-30 | Irm Llc | Compounds and compositions as trk inhibitors |
| CN102827186A (zh) * | 2011-06-16 | 2012-12-19 | 中国科学院上海药物研究所 | 一类吡啶并五元杂环衍生物及其制备方法和用途 |
| WO2013022519A1 (en) * | 2011-08-10 | 2013-02-14 | Merck Patent Gmbh | Pyrido-pyrimidine derivatives |
| WO2013043715A1 (en) * | 2011-09-19 | 2013-03-28 | Genentech, Inc. | Combination treatments comprising c-met antagonists and b-raf antagonists |
| WO2013074633A1 (en) * | 2011-11-14 | 2013-05-23 | Cephalon, Inc. | Uracil derivatives as axl and c-met kinase inhibitors |
| WO2013180949A1 (en) * | 2012-05-27 | 2013-12-05 | Ning Xi | Substituted quinoline compounds and methods of use |
Non-Patent Citations (2)
| Title |
|---|
| SCHROEDER, G. M. ET AL.: "Discovery of N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-ox", JOURNAL OF MEDICINAL CHEMISTRY, vol. 52(5), JPN6018039702, 2009, pages 1251 - 1254, ISSN: 0003894529 * |
| SUAREZ, R. M. ET AL: "Inhibitors of the TAM subfamily of tyrosine kinases: Synthesis and biological evaluation", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 61, JPN6018039704, 2013, pages 2 - 25, ISSN: 0003894530 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021504367A (ja) * | 2017-11-24 | 2021-02-15 | 南京明徳新薬研発有限公司Ｍｅｄｓｈｉｎｅ Ｄｉｓｃｏｖｅｒｙ Ｉｎｃ． | ｃ−ＭＥＴ／ＡＸＬ阻害剤としてのウラシル系化合物 |
| JP7377798B2 (ja) | 2017-11-24 | 2023-11-10 | 南京明徳新薬研発有限公司 | ｃ－ＭＥＴ／ＡＸＬ阻害剤としてのウラシル系化合物 |
| JP2021536436A (ja) * | 2018-08-24 | 2021-12-27 | 南京薬捷安康生物科技有限公司Nanjing Transthera Biosciences Co., Ltd. | キノリン誘導体から調製される新規な阻害剤 |
| WO2023286719A1 (ja) * | 2021-07-13 | 2023-01-19 | 日本曹達株式会社 | ウラシル化合物の製造方法 |
| JPWO2023286719A1 (enExample) * | 2021-07-13 | 2023-01-19 |
Also Published As
| Publication number | Publication date |
|---|---|
| EA201890061A2 (ru) | 2018-05-31 |
| EA029757B1 (ru) | 2018-05-31 |
| CA2934667A1 (en) | 2015-07-02 |
| PL3087070T3 (pl) | 2018-03-30 |
| PT3087070T (pt) | 2018-01-30 |
| NO3014707T3 (enExample) | 2018-01-06 |
| AU2014370186A2 (en) | 2016-07-21 |
| CN106029661B (zh) | 2017-11-03 |
| US9914731B2 (en) | 2018-03-13 |
| US20180148447A1 (en) | 2018-05-31 |
| PH12016501232A1 (en) | 2016-08-15 |
| HUE037579T2 (hu) | 2018-09-28 |
| ES2654931T3 (es) | 2018-02-15 |
| WO2015100117A1 (en) | 2015-07-02 |
| CN106029661A (zh) | 2016-10-12 |
| SI3087070T1 (en) | 2018-01-31 |
| BR112016015057A2 (pt) | 2017-08-08 |
| AU2014370186A1 (en) | 2016-07-14 |
| EA201691164A1 (ru) | 2016-12-30 |
| MX2016008445A (es) | 2016-10-28 |
| KR20160110390A (ko) | 2016-09-21 |
| EP3087070B1 (en) | 2017-11-08 |
| IL246311A0 (en) | 2016-08-02 |
| CL2016001604A1 (es) | 2017-05-26 |
| DK3087070T3 (en) | 2017-12-04 |
| EA201890061A3 (ru) | 2018-09-28 |
| SG11201605207PA (en) | 2016-07-28 |
| US20160318929A1 (en) | 2016-11-03 |
| EP3087070A1 (en) | 2016-11-02 |
| EP3309160A1 (en) | 2018-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3087070B1 (en) | Pyrazolo[1,5-a]pyridine derivatives and methods of their use | |
| KR101467593B1 (ko) | Ｆｇｆｒ 억제제로서의 아실아미노피라졸 | |
| KR102374844B1 (ko) | 이소퀴놀린-3-일 카르복스아마이드 및 이의 제제와 용도 | |
| JP6692350B2 (ja) | リジン特異的なデメチラーゼ−１の阻害剤 | |
| JP7038414B2 (ja) | ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子 | |
| JP6430512B2 (ja) | リジン特異的デメチラーゼ−１の阻害剤 | |
| AU2013210438B2 (en) | Pyrazine carboxamide compound | |
| KR102181915B1 (ko) | Trka 키나아제 억제제로서 n-피롤리디닐, n'-피라졸릴-우레아, 티오우레아, 구아니딘 및 시아노구아니딘 화합물 | |
| AU2008289037B2 (en) | 5- (4- (haloalkoxy) phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors | |
| JP6377081B2 (ja) | 新規ピリミジン化合物 | |
| CN112638373A (zh) | 细胞周期蛋白依赖性激酶抑制剂 | |
| JP2009541268A (ja) | Ｍｎｋキナーゼ阻害剤としてのピリジンおよびピラジン誘導体 | |
| CN107141293A (zh) | 一种含氮杂环化合物、制备方法、中间体、组合物和应用 | |
| JP2017522346A (ja) | ブロモドメインに対して活性な化合物 | |
| WO2013100672A1 (ko) | 단백질 키나아제 저해활성을 가지는 3,6-이치환된 인다졸 유도체 | |
| CA2607874A1 (en) | Quinoline derivatives as neurokinin receptor antagonists | |
| US20230227428A1 (en) | Amido compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160830 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171215 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171215 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180913 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181009 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20181219 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190604 |